Close Menu

NEW YORK – Luminex said Monday that the US Food and Drug Administration has issued an Emergency Use Authorization (EUA) for its Aries SARS-CoV-2 Assay for rapid detection of the virus that causes COVID-19.

The assay runs on the FDA-cleared Aries System, a sample-to-answer molecular diagnostic platform that can perform 144 tests per day. It will allow hospital professionals to determine the appropriate course of treatment for patients suspected of having COVID-19 within approximately two hours, Luminex said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.

The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.

A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.

In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.